Paris October 24, 2005- Effective october 2oo5, Jean-Yves Wessely is appointed Senior Vice President in charge of Winthrop, worldwide Generics Activities of sanofi-aventis, based in Paris. Jean-Yves Wessely, MD, brings with him a wealth of more than 25 years of experience in the pharmaceutical industry, as well as an intimate knowledge of Winthrop's key markets, having held several regional a
Paris, 2005-10-20: Adults with type 2 diabetes taking Exubera (insulin human) alone or in combination with diabetes pills achieved significantly greater reductions in blood sugar levels compared to patients taking pills alone, according to a new study published in the October issue of Annals of Internal Medicine. Läs mer i bifogad fil. See attached document.
Paris October 14, 2005 Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of EXUBERA (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes. The proposed therapeutic indication for Exubera is for the treatment of adult pati
MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 Data presented today at the 15th Annual Internati
INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv
Studies show impact of enforced titration of Lantus® (insulin glargine) on reducing HbA1C levels, and Apidra® (insulin glulisine) on postprandial glucose control in patients with type 2 diabetes Athens September 14th, 2005: Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens show that a strictly enforced titration schedule with intensiv
Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products
I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel
Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoats revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the worlds 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&
- Hoechst AG, a subsidiary of sanofi-aventis, and the Wacker family agreed on the restructuring of the ownership of Wacker-Chemie GmbH.
Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers Läs mer http://en.sanofi-aventis.com/index.asp
Läs mer på http://en.sanofi-aventis.com/press/p_press.asp
Strong net sales growth in the first half of 2005: 11.0% on a comparable basis. Further increase in market share in the second quarter.
- Sanofi-aventis and Daiichi Pharmaceutical Co., Ltd. announced today the transfer of all commercial rights for Plavix® (clopidogrel) in Japan from Daiichi and a jointly held partnership to sanofi-aventis Japan. The transfer will be implemented in conformity with local regulatory requirements. Given their long-standing partnership, both parties agreed to collaborate in the future in the areas
Understanding the Factors Which Contribute to Bone Strength Geneva, Switzerland, 28 June, 2005 The Alliance for Better Bone Health announced today that according to evidence presented by an international panel of osteoporosis experts, Bone Mineral Density (BMD) testing does not accurately reflect all factors important to bone strength. The panels findings, presented at the Second Joint Meetin
Contact: sanofi-aventis Jean Marc Podvin +33 (0)1 53 77 42 23 Salah Mahyaoui +33 (0)1 53 77 40 31 +33 (0)6 73 68 78 88 Bristol-Myers Squibb Rob Hutchinson +1 609 252 3901 +1 609 271 2704 Recent clinical findings have demonstrated that a large majority of hypertensive patients who failed to achieve blood pressure goal on monotherapy can be helped to attain goal with the angiotensin-I
On June 15, 2005, the U.S. District Court for the Central District of California granted the Motion for Summary Judgment for inequitable conduct filed by Amphastar Pharmaceuticals, Inc. in the sanofi-aventis Groups suit against Amphastar and Teva Pharmaceuticals USA, Inc. for infringement of US Patent no. 5,389,618 ('618 patent") by their proposed generic versions of Lovenox®. A formal entry o
Two studies show insulin glargine control of HbA1C in poorly controlled type 2 diabetes patients, with comparable rates of hypoglycemia Data presented today at the 65th Session of the American Diabetes Association (ADA), San Diego demonstrated that people with type 2 diabetes achieved significantly better glycaemic control, and also achieve it earlier, when treated with the 24-hour basal insuli
First and Only Booster in the U.S. for Protection against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has licensed ADACEL (Tetanus Toxoid and Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) Vaccine for protection against tetanus, d